Ines Domingues
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ines Domingues has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Susana Constantino Rosa Santos
Department of Radiation Oncology, Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
2 shared publications - Angelo Calado
Unidade de Biologia Microvascular e Inflamação, Instituto de Medicina Molecular, Instituto de Bioquímica, Faculdade de Medicina, Universidade de Lisboa, Portugal
1 shared publication Cláudia Miguel
1 shared publication- Jeroen A. A. Demmers
Proteomics Center, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication - José Rino
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
1 shared publication Primal de Lanerolle
Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, Illinois, United States of America
1 shared publication
Latest Publications
- Open Access
- 28 September 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (9) , e25668
VEGFR2 Translocates to the Nucleus to Regulate Its Own Transcription
Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) is the major mediator of the angiogenic effects of VEGF. In addition to its well known role as a membrane receptor that activates multiple signaling pathways, VEGFR2 also has a nuclear localization. However, what VEGFR2 does in the nucleus is still unknown. In the present report we show that, in endothelial cells, nuclear VEGFR2 interacts with several nuclear proteins, including the Sp1, a transcription factor that has been implicated in the regulation of genes needed for angiogenesis. By in vivo chromatin immunoprecipitation (ChIP) assays, we found that VEGFR2 binds to the Sp1-responsive region of the VEGFR2 proximal promoter. These results were confirmed by EMSA assays, using the same region of the VEGFR2 promoter. Importantly, we show that the VEGFR2 DNA binding is directly linked to the transcriptional activation of the VEGFR2 promoter. By reporter assays, we found that the region between -300/-116 relative to the transcription start site is essential to confer VEGFR2-dependent transcriptional activity. It was previously described that nuclear translocation of the VEGFR2 is dependent on its activation by VEGF. In agreement, we observed that the binding of VEGFR2 to DNA requires VEGF activation, being blocked by Bevacizumab and Sunitinib, two anti-angiogenic agents that inhibit VEGFR2 activation. Our findings demonstrate a new mechanism by which VEGFR2 activates its own promoter that could be involved in amplifying the angiogenic response.
- 28 September 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (9) , e25668
Open AccessVEGFR2 Translocates to the Nucleus to Regulate Its Own Transcription
Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) is the major mediator of the angiogenic effects of VEGF. In addition to its well known role as a membrane receptor that activates multiple signaling pathways, VEGFR2 also has a nuclear localization. However, what VEGFR2 does in the nucleus is still unknown. In the present report we show that, in endothelial cells, nuclear VEGFR2 interacts with several nuclear proteins, including the Sp1, a transcription factor that has been implicated in the regulation of genes needed for angiogenesis. By in vivo chromatin immunoprecipitation (ChIP) assays, we found that VEGFR2 binds to the Sp1-responsive region of the VEGFR2 proximal promoter. These results were confirmed by EMSA assays, using the same region of the VEGFR2 promoter. Importantly, we show that the VEGFR2 DNA binding is directly linked to the transcriptional activation of the VEGFR2 promoter. By reporter assays, we found that the region between -300/-116 relative to the transcription start site is essential to confer VEGFR2-dependent transcriptional activity. It was previously described that nuclear translocation of the VEGFR2 is dependent on its activation by VEGF. In agreement, we observed that the binding of VEGFR2 to DNA requires VEGF activation, being blocked by Bevacizumab and Sunitinib, two anti-angiogenic agents that inhibit VEGFR2 activation. Our findings demonstrate a new mechanism by which VEGFR2 activates its own promoter that could be involved in amplifying the angiogenic response.
- 1 May 2007
- Published by Elsevier in Experimental Cell Research
- Vol. 313 (8) , 1561-1574
VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing
- 1 May 2007
- Published by Elsevier in Experimental Cell Research
- Vol. 313 (8) , 1561-1574
VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing